CPRXCatalyst Pharmaceuticals, Inc.

$3B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$36M+22.6% YoY

Gross Profit

$31M85.2% margin

Operating Income

$14M38.9% margin

Net Income

$10M28.7% margin

EPS (Diluted)

$0.10

QoQ Revenue Growth

-1.1%

Cash Flow

Operating Cash Flow

$22M

Free Cash Flow

$22M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$223M

Total Liabilities

$25M

Stockholders' Equity

$199M

Cash & Equivalents

$155M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$36M	$29M	+22.6%
Gross Profit	$31M	$25M	+20.5%
Operating Income	$14M	$12M	+19.7%
Net Income	$10M	$43M	-76.2%

Revenue Segments

Product Revenue, Net

$36M100%

CPRX Q3 2021 Earnings — Catalyst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena